利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

17 条记录 (耗时 0.021 秒)

    METHODS FOR THE DIAGNOSIS AND TREATMENT OF CYTOKINE RELEASE SYNDROME
    9.
    发明公开
    METHODS FOR THE DIAGNOSIS AND TREATMENT OF CYTOKINE RELEASE SYNDROME 审中-公开

    公开(公告)号：EP4424711A3

    公开(公告)日：2024-10-23

    申请号：EP24184659.1

    申请日：2021-05-19

    申请人： Institut Curie ,  Institut National de la Santé et de la Recherche Médicale (INSERM) ,  Centre National de la Recherche Scientifique

    发明人： RODRIGUEZ, Raphaël ,  MULLER, Sebastian ,  SOLIER, Stéphanie ,  WATSON, Sarah

    IPC分类号： A61K33/26 ,  A61K39/395 ,  A61P29/00 ,  A61P37/02 ,  A61P39/04 ,  C07K16/28

    摘要： The invention relates to methods and pharmaceutical compositions for the treatment of Cytokine Release Syndrome (CRS). The invention also relates to methods for the diagnosis of patients suffering from Cytokine Release Syndrome.The inventors investigate iron homeostasis and the role of CD44-mediated iron endocytosis in the severe inflammatory response and Cytokine Release Syndrome, particularly in SARS-CoV-2 patients. The inventors demonstrate that during activation of M1 macrophages, iron endocytosis is upregulated in a CD44-dependent manner and that CD44 protein levels increase. This effect is specific to M1 macrophages, whereas levels of the canonical iron endocytosis protein TfR1/CD71 remain unchanged. In the present invention, the inventors provide in vitro evidences towards a direct role of CD44-mediated iron endocytosis in the severe inflammatory response such as Cytokine Release Syndrome observed in SARS-CoV-2 patients. Thus, the present invention relates to an antagonist of CD44/Hyaluronic Acid pathway for use in the treatment of cytokine release syndrome in a subject in need thereof, particularly severe COVID-19-related cytokine release syndrome.